Johnson & Johnson Forecast, price target & analysts
Johnson & Johnson Target price 2025 - Analyst rating & recommendation
Johnson & Johnson Classifications & Recommendation:
Johnson & Johnson Price Target
| Target Price | $171.68 |
| Price | $155.66 |
| Potential | 10.29% |
| Number of Estimates | 19 |
| 19 Analysts have issued a price target Johnson & Johnson 2026 . The average Johnson & Johnson target price is $171.68. This is 10.29% higher than the current stock price. The highest price target is $185.00 18.85% , the lowest is $155.00 0.42% . | |
| A rating was issued by 25 analysts: 12 Analysts recommend Johnson & Johnson to buy, 13 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Johnson & Johnson stock has an average upside potential 2026 of 10.29% . Most analysts recommend the Johnson & Johnson stock at Hold. |
Sales and Margin forecast 2025, 2026 to 2029
18 Analysts have issued a sales forecast Johnson & Johnson 2025 . The average Johnson & Johnson sales estimate is $91.3b . This is 2.21% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $91.9b 2.85% , the lowest is $90.4b 1.21% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $88.8b | 4.31% |
|---|---|---|
| 2025 | $91.3b | 2.80% |
| 2026 | $95.1b | 4.18% |
| 2027 | $99.4b | 4.53% |
| 2028 | $103b | 3.51% |
| 2029 | $109b | 6.00% |
13 Analysts have issued an Johnson & Johnson EBITDA forecast 2025. The average Johnson & Johnson EBITDA estimate is $34.3b . This is 20.00% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $38.8b 35.81% , the lowest is $31.0b 8.59% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $28.2b | 5.01% |
|---|---|---|
| 2025 | $34.3b | 21.80% |
| 2026 | $35.7b | 3.93% |
| 2027 | $37.9b | 6.41% |
| 2028 | $39.7b | 4.61% |
| 2029 | $39.2b | 1.26% |
EBITDA Margin
| 2024 | 31.71% | 8.93% |
|---|---|---|
| 2025 | 37.57% | 18.49% |
| 2026 | 37.48% | 0.24% |
| 2027 | 38.15% | 1.79% |
| 2028 | 38.56% | 1.07% |
| 2029 | 35.92% | 6.85% |
6 Johnson & Johnson Analysts have issued a net profit forecast 2025. The average Johnson & Johnson net profit estimate is $26.3b . This is 21.61% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $27.3b 26.11% , the lowest is $25.5b 17.78% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $13.9b | 4.70% |
|---|---|---|
| 2025 | $26.3b | 89.03% |
| 2026 | $24.9b | 5.46% |
| 2027 | $27.8b | 11.62% |
Net Margin
| 2024 | 15.68% | 0.38% |
|---|---|---|
| 2025 | 28.84% | 83.91% |
| 2026 | 26.17% | 9.26% |
| 2027 | 27.94% | 6.76% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
6 Analysts have issued a Johnson & Johnson forecast for earnings per share. The average Johnson & Johnson EPS is $10.95 . This is 21.67% higher than earnings per share in the financial year 2024. The highest EPS forecast is $11.35 26.11% , the lowest is $10.60 17.78% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $5.79 | 4.70% |
|---|---|---|
| 2025 | $10.95 | 89.12% |
| 2026 | $10.35 | 5.48% |
| 2027 | $11.55 | 11.59% |
P/E ratio
| Current | 17.30 | 19.53% |
|---|---|---|
| 2025 | 14.22 | 17.80% |
| 2026 | 15.04 | 5.77% |
| 2027 | 13.48 | 10.37% |
Based on analysts' sales estimates for 2025, the Johnson & Johnson stock is valued at an EV/Sales of 4.26 and an P/S ratio of 4.11 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.35 | 6.36% |
|---|---|---|
| 2025 | 4.26 | 2.16% |
| 2026 | 4.09 | 4.02% |
| 2027 | 3.91 | 4.33% |
| 2028 | 3.78 | 3.40% |
| 2029 | 3.56 | 5.66% |
P/S ratio
| Current | 4.20 | 4.67% |
|---|---|---|
| 2025 | 4.11 | 2.16% |
| 2026 | 3.94 | 4.01% |
| 2027 | 3.77 | 4.33% |
| 2028 | 3.64 | 3.40% |
| 2029 | 3.44 | 5.66% |
Johnson & Johnson...
Current Johnson & Johnson Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Apr 17 2025 |
| Raymond James |
Outperform
➜
Outperform
|
Unchanged | Apr 16 2025 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Apr 16 2025 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 16 2025 |
| Raymond James |
Outperform
➜
Outperform
|
Unchanged | Apr 14 2025 |
| B of A Securities |
Neutral
➜
Neutral
|
Unchanged | Apr 10 2025 |
| Goldman Sachs |
Neutral
➜
Buy
|
Upgrade | Apr 09 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
Apr 17 2025 |
|
Unchanged
Raymond James:
Outperform
➜
Outperform
|
Apr 16 2025 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Apr 16 2025 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Apr 16 2025 |
|
Unchanged
Raymond James:
Outperform
➜
Outperform
|
Apr 14 2025 |
|
Unchanged
B of A Securities:
Neutral
➜
Neutral
|
Apr 10 2025 |
|
Upgrade
Goldman Sachs:
Neutral
➜
Buy
|
Apr 09 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
